Bioventus stockholders approve 2023 Retention Equity Award Plan authorizing 600K shares

Bioventus Inc.

Stockholders approved 2023 Retention Equity Award Plan, reserving 600,000 shares of Class A common stock for RSUs.
Plan aims to retain critical employees; no awards granted yet; Board approved April 17, 2023, stockholders June 7.
All five Class II director nominees elected with strong shareholder support (82-86% 'for' of votes cast).
Grant Thornton LLP ratified as independent auditor for FY 2023 with 99.9% 'for' votes.
Meeting had 88.78% of outstanding shares represented; about 69.5 million shares voted.

item 5.02 item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Bioventus Inc. shareholders approved Election of Class II Directors.

Proposal: director election
Outcome: passed

Exact text from the filing

Nominee For Withheld Broker Non-Votes John A. Bartholdson 59,864,373 977,795 8,674,061 Patrick J. Beyer 58,954,599 1,887,569 8,674,061 William A. Hawkins 58,254,590 2,587,578 8,674,061 Mary Kay Ladone 58,552,359 2,289,809 8,674,061 Susan M. Stalnecker 58,586,174 2,255,994 8,674,061

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.7

Bioventus Inc. shareholders approved Approval of the 2023 Plan.

Proposal: equity plan
Outcome: passed

Exact text from the filing

The stockholders also approved the 2023 Plan described in

View on SEC.gov

Browse all shareholder votes →

Bioventus Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-021758

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.